BioCardia, Inc.
$1.25
▲
3.45%
2026-04-21 05:35:01
www.biocardia.com
NCM: BCDA
Explore BioCardia, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.91 M
Current Price
$1.25
52W High / Low
$3.2 / $1
Stock P/E
—
Book Value
$0.08
Dividend Yield
—
ROCE
-843.83%
ROE
-9.5%
Face Value
—
EPS
$-1.23
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
0.55
Debt / Equity
58.99
Current Ratio
1.12
Quick Ratio
1.12
Forward P/E
-2.11
Price / Sales
—
Enterprise Value
$10.94 M
EV / EBITDA
-1.33
EV / Revenue
—
Rating
None
Target Price
$15.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NRx Pharmaceuticals, Inc. | $3.2 | — | $105.82 M | — | 103.85% | 146.18% | $3.84 / $1.62 | $-0.5 |
| 2. | Sana Biotechnology, Inc. | $3.82 | — | $939.37 M | — | -60.83% | -1.19% | $6.55 / $1.53 | $0.6 |
| 3. | Dermata Therapeutics, Inc. | $1.34 | — | $5.47 M | — | -124.91% | -1.94% | $9.9 / $1.1 | $2.34 |
| 4. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 5. | Royalty Pharma plc | $49.52 | 27.78 | $28.52 B | 1.91% | 8.21% | 13.2% | $50.08 / $31.58 | $15.11 |
| 6. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
| 7. | VYNE Therapeutics Inc. | $0.63 | — | $20.33 M | — | -107.15% | -66.96% | $1.99 / $0.28 | $0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.01 M | -1.49 M | -2.05 M | -2.73 M | -2.32 M | — |
| Net Profit | -1.98 M | -1.48 M | -2.05 M | -2.71 M | -2.3 M | — |
| EPS in Rs | -0.18 | -0.14 | -0.19 | -0.25 | -0.21 | -0.61 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.06 M | 0.48 M | 1.35 M |
| Operating Profit | -8.28 M | -8 M | -11.64 M | -11.9 M |
| Net Profit | -8.23 M | -7.95 M | -11.57 M | -11.91 M |
| EPS in Rs | -0.75 | -0.73 | -1.06 | -1.09 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.41 M | 3.72 M | 2.99 M | 9.79 M |
| Total Liabilities | 2.52 M | 2.89 M | 4.59 M | 4.9 M |
| Equity | 0.9 M | 0.84 M | -1.6 M | 4.89 M |
| Current Assets | 2.73 M | 2.62 M | 1.46 M | 7.86 M |
| Current Liabilities | 2.43 M | 2.32 M | 3.61 M | 3.58 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.44 M | -7.89 M | -9.97 M | -10.56 M |
| Investing CF | -0.01 M | -0.01 M | -0.01 M | -0.07 M |
| Financing CF | 7.57 M | 9.16 M | 3.73 M | 5.12 M |
| Free CF | -7.44 M | -7.89 M | -9.99 M | -10.63 M |
| Capex | -0.01 M | -0.01 M | -0.01 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -87.84% | -64.72% | — | — |
| Earnings Growth % | 31.33% | 2.82% | — | — |
| Profit Margin % | -13700% | -2425.79% | -880.7% | — |
| Operating Margin % | -13794.83% | -2441.09% | -880.25% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -13679.31% | -2423.48% | -874.19% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-05-30 | 1:0.0666667 |